Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.24 +5.4%	$0.36	$0.14 ▼ $1.27	$9.95M	1.79	5.70 million shs	427,763 shs
ERNA Ernexa Therapeutics	$1.49 +4.0%	$1.88	$1.43 ▼ $28.65	$11.43M	5.42	299,573 shs	12,800 shs
IBIO iBio	$0.79 -6.9%	$0.73	$0.56 ▼ $6.89	$15.47M	0.6	1.55 million shs	18.07 million shs
UBX UNITY Biotechnology	$0.18 -40.4%	$0.43	$0.20 ▼ $3.10	$3.08M	0.92	284,137 shs	3.73 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	-4.32%	-19.07%	-41.80%	+18.84%	-80.02%
ERNA Ernexa Therapeutics	-4.47%	-10.99%	-26.51%	-60.03%	-94.84%
IBIO iBio	+6.93%	+13.87%	+15.37%	+4.60%	-58.33%
UBX UNITY Biotechnology	0.00%	0.00%	0.00%	-75.74%	-88.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	2.9506 of 5 stars	3.4	5.0	0.0	0.0	2.4	0.8	0.6
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.8262 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.0	0.6
UBX UNITY Biotechnology	2.2592 of 5 stars	3.2	0.0	0.0	4.7	0.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	708.82% Upside
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	535.24% Upside
UBX UNITY Biotechnology	2.33	Hold	$2.33	1,203.54% Upside

Current Analyst Ratings Breakdown

Latest UBX, IBIO, CARM, and ERNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$10.77M	0.92	N/A	N/A	($0.67) per share	-0.36
ERNA Ernexa Therapeutics	$580K	19.57	N/A	N/A	$0.50 per share	2.96
IBIO iBio	$375K	41.25	N/A	N/A	$1.41 per share	0.56
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	$0.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2025 (Estimated)
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-682.08%	11/10/2025 (Estimated)
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	N/A

Latest UBX, IBIO, CARM, and ERNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
ERNA Ernexa Therapeutics	N/A	1.81	1.81
IBIO iBio	0.05	1.76	1.76
UBX UNITY Biotechnology	N/A	1.95	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
ERNA Ernexa Therapeutics	70.55%
IBIO iBio	7.90%
UBX UNITY Biotechnology	29.49%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
ERNA Ernexa Therapeutics	4.49%
IBIO iBio	0.58%
UBX UNITY Biotechnology	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
ERNA Ernexa Therapeutics	10	7.67 million	7.33 million	No Data
IBIO iBio	100	19.66 million	9.82 million	N/A
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable

UBX, IBIO, CARM, and ERNA Headlines

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice

June 30, 2025 | finance.yahoo.com

Unity Biotechnology stock plunges after Nasdaq delisting notice

June 30, 2025 | za.investing.com

Unity Biotechnology Inc News (UBX) - Investing.com

June 26, 2025 | investing.com

UBX Unity Biotechnology, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)

May 28, 2025 | msn.com

Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities

May 18, 2025 | theglobeandmail.com

Bay Area biotech company Unity lays off every single worker, including CEO

May 6, 2025 | msn.com

Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce

May 5, 2025 | msn.com

South San Francisco biotech company lays off entire workforce, including CEO

May 5, 2025 | msn.com

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles

May 5, 2025 | fiercebiotech.comF

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

May 1, 2025 | globenewswire.com

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

April 25, 2025 | ophthalmologytimes.comO

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

April 22, 2025 | globenewswire.com

Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology price target lowered to $4 from $6 at Chardan

March 26, 2025 | markets.businessinsider.com

Unity Biotechnology announces results from ASPIRE Phase 2b study in DME

March 25, 2025 | markets.businessinsider.com

Unity reports topline outcomes from trial of diabetic macular oedema therapy

March 25, 2025 | msn.com

UNITY Biotechnology tanks on mixed results for eye disease drug

March 25, 2025 | thepharmaletter.comT

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

March 25, 2025 | zacks.com

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

March 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX, IBIO, CARM, and ERNA Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.24 +0.01 (+5.40%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 0.00 (-1.26%)

As of 07:39 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Ernexa Therapeutics NASDAQ:ERNA

$1.49 +0.06 (+3.98%)

Closing price 03:59 PM Eastern

Extended Trading

$1.52 +0.02 (+1.68%)

As of 06:23 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

iBio NYSE:IBIO

$0.79 -0.06 (-6.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.24%)

As of 07:43 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time